While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...
If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...
Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...
We recently compiled a list of the Jim Cramer Remembers COVID-19 & Discusses These 11 Stocks. In this article, we are going ...